Japanese Drug Makers Encounter High Prices For Foreign M&As
This article was originally published in PharmAsia News
Executive Summary
Despite the current global economy, Japanese drug makers seeking acquisitions abroad continue to face demands for high prices for buyout proposals. Japanese pharmas, still cash-rich, seek access to foreign markets to make up for declining sales at home where the government is pressing for purchases of more generics to replace branded drugs. Together, Japanese drug makers have spent more than $20 billion the past year on foreign acquisitions. Would-be sellers, though, appear aware their properties are valuable to the Japanese. (Click here for more